Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences, a US based discoverer, developer and commercializer of therapeutics in the areas of unmet medical need, has reported total revenues of $2.14bn for the second quarter ended 30 June 2011, an increase of 11% as compared to $1.93bn for the same period in 2010.
Subscribe to our email newsletter
Gilead Sciences‘ net income was $746.23m, compared to $712.06m for the same period in the prior year.
The company’s income from operations was $1.02bn for the second quarter ended 30 June 2011, as compared to $992.63m for the same period in 2010.
For the six months ended 30 June 2011 total revenue were $4.06bn, compared to $4.01bn for the same period in 2010.
Net income was $1.4bn for the six months ended 30 June 2011, as compared to $1.57bn for the same period prior year.
For the six months ended 30 June 2011, the company’s income from operations were $1.92bn , as compared to $2.15bn for the same period in 2010.